Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 8/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13843586 | 0.81 | CA12 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2645323 | 0.80 | CA12 (0.39) | CA12CA1CA2CA9CA14 | |
| SCHEMBL20377738 | 0.79 | POLB (0.59) | CHRNB2CHRNA4F10POLB | |
| SCHEMBL18376864 | 0.79 | CHRNB2 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1044182 | 0.79 | ELANE (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27252424 | 0.79 | F10 (0.40) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18708822 | 0.77 | HRH4 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27961217 | 0.75 | POLB (0.59) | CHRNB2CHRNA4PDPK1SMN1; SMN2NOS3 | |
| SCHEMBL76912 | 0.75 | SMN1; SMN2 (0.52) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4729570 | 0.75 | MCHR1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1671949-B1 | Substituted Pyridinylamines | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | claimed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | claimed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | claimed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4136073-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Gossamer Bio Services, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| WO-2021211741-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211741-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | CA12 4616/4885CA1 4851/4885CA2 4658/4885 |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK3, TYK2, IRAK2 | CA12 3305/4885CA1 4774/4885CA2 3637/4885 |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | CA12 4536/4885CA1 4857/4885CA2 4677/4885 |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | CA12 646/4885CA1 540/4885CA2 1283/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | CA12 1223/4885CA1 662/4885CA2 1577/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | CA12 1125/4885CA1 310/4885CA2 1185/4885 |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | CA12 1116/4885CA1 945/4885CA2 2885/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CA12 4536/4885CA1 4857/4885CA2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.